CING
Cingulate Inc. [CING] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CING Stock Summary
Top 10 Correlated ETFs
CING
Top 10 Correlated Stocks
CING
In the News
CING Financial details
Company Rating
-
Market Cap
3.66M
Income
-178.58M
Revenue
3.85B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-0.87
Forward P/E
-
PEG
-0.01
P/S
-
P/B
-1555.33
P/C
-
P/FCF
-0.42
Quick Ratio
0.35
Current Ratio
0.51
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-304.57
EPS next Y
-
EPS next Q
-
EPS this Y
-17.64%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-1.82%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-2937%
ROE
913%
ROC
-190%
Gross Margin
-65%
Oper. Margin
-1%
Profit Margin
-4%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.9201-23.8
52W High
-
52W Low
-
RSI
42
Rel Volume
0.32
Avg Volume
320.48K
Volume
103.17K
Perf Week
-1.37%
Perf Month
1.69%
Perf Quarter
-9.55%
Perf Half Y
-17.24%
-
-
-
-
Beta
-0.959
-
-
Volatility
0.11%, 0.22%
Prev Close
1.12%
Price
3.6
Change
-2.44%
Company Profile
- Volume Average 320.48K
- Market Capitalization 3.66M
- Employee 13
- CEO Dr. Shane J. Schaffer Pharm.D., PharmD
- Headquarters Kansas City,KS,US
- IPO Date 2021-12-08
-
Website
https://www.cingulate.com 
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
